PubRank

Un Jung Kang

Author PubWeight™ 47.05‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression. Ann Neurol 2011 2.84
2 Characterization of PINK1 processing, stability, and subcellular localization. J Neurochem 2008 2.29
3 Age-dependent motor deficits and dopaminergic dysfunction in DJ-1 null mice. J Biol Chem 2005 1.75
4 Genetic engineering of mouse embryonic stem cells by Nurr1 enhances differentiation and maturation into dopaminergic neurons. Eur J Neurosci 2002 1.75
5 Enhanced striatal cholinergic neuronal activity mediates L-DOPA-induced dyskinesia in parkinsonian mice. Proc Natl Acad Sci U S A 2010 1.74
6 Selective loss of dopaminergic neurons in the substantia nigra of Pitx3-deficient aphakia mice. Brain Res Mol Brain Res 2003 1.66
7 Behavioral models of Parkinson's disease in rodents: a new look at an old problem. Mov Disord 2006 1.49
8 The effects of chronic L-DOPA therapy on pharmacodynamic parameters in a rat model of motor response fluctuations. Exp Neurol 2003 1.48
9 Genetic selection of sox1GFP-expressing neural precursors removes residual tumorigenic pluripotent stem cells and attenuates tumor formation after transplantation. J Neurochem 2006 1.46
10 Unregulated cytosolic dopamine causes neurodegeneration associated with oxidative stress in mice. J Neurosci 2008 1.43
11 Effects of low to moderate acute doses of pramipexole on impulsivity and cognition in healthy volunteers. J Clin Psychopharmacol 2008 1.34
12 The homeodomain transcription factor Pitx3 facilitates differentiation of mouse embryonic stem cells into AHD2-expressing dopaminergic neurons. Mol Cell Neurosci 2005 1.29
13 Neural precursors derived from human embryonic stem cells maintain long-term proliferation without losing the potential to differentiate into all three neural lineages, including dopaminergic neurons. J Neurochem 2007 1.22
14 Stromal cell-derived inducing activity, Nurr1, and signaling molecules synergistically induce dopaminergic neurons from mouse embryonic stem cells. Stem Cells 2005 1.22
15 Dopamine-dependent motor learning: insight into levodopa's long-duration response. Ann Neurol 2010 1.12
16 Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. J Parkinsons Dis 2012 1.09
17 Paraquat induces dopaminergic dysfunction and proteasome impairment in DJ-1-deficient mice. Hum Mol Genet 2007 1.05
18 Neural precursors derived from embryonic stem cells, but not those from fetal ventral mesencephalon, maintain the potential to differentiate into dopaminergic neurons after expansion in vitro. Stem Cells 2006 1.05
19 Effect of stimulation frequency on immediate freezing of gait in newly activated STN DBS in Parkinson's disease. J Neurol Neurosurg Psychiatry 2012 1.01
20 Longitudinal assessment of tau and amyloid beta in cerebrospinal fluid of Parkinson disease. Acta Neuropathol 2013 1.00
21 Chronic 3,4-dihydroxyphenylalanine treatment induces dyskinesia in aphakia mice, a novel genetic model of Parkinson's disease. Neurobiol Dis 2007 0.99
22 Distinct mechanisms of neurodegeneration induced by chronic complex I inhibition in dopaminergic and non-dopaminergic cells. J Biol Chem 2004 0.96
23 The antioxidant Trolox helps recovery from the familial Parkinson's disease-specific mitochondrial deficits caused by PINK1- and DJ-1-deficiency in dopaminergic neuronal cells. Mitochondrion 2011 0.94
24 MPTP administration in mice changes the ratio of splice isoforms of fosB and rgs9. Brain Res 2007 0.93
25 Structural determinants of PINK1 topology and dual subcellular distribution. BMC Cell Biol 2010 0.88
26 Loss of PINK1 attenuates HIF-1α induction by preventing 4E-BP1-dependent switch in protein translation under hypoxia. J Neurosci 2014 0.87
27 The surfactant poloxamer-188 protects against glutamate toxicity in the rat brain. Neuroreport 2004 0.87
28 Regulation of the noradrenaline neurotransmitter phenotype by the transcription factor AP-2beta. J Biol Chem 2008 0.85
29 Phosphorylated α-synuclein in Parkinson's disease: correlation depends on disease severity. Acta Neuropathol Commun 2015 0.84
30 A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008 0.84
31 Striatal cholinergic cell ablation attenuates L-DOPA induced dyskinesia in Parkinsonian mice. J Neurosci 2014 0.83
32 The role of neuroplasticity in dopaminergic therapy for Parkinson disease. Nat Rev Neurol 2013 0.83
33 Role of DaTSCAN and clinical diagnosis in Parkinson disease. Neurology 2012 0.83
34 Surfactant poloxamer 188-related decreases in inflammation and tissue damage after experimental brain injury in rats. J Neurosurg 2004 0.81
35 Poloxamer 188 volumetrically decreases neuronal loss in the rat in a time-dependent manner. Neurosurgery 2004 0.81
36 Transcription factor AP-2β regulates the neurotransmitter phenotype and maturation of chromaffin cells. Mol Cell Neurosci 2010 0.77
37 DBS reduced hemichorea associated with a developmental venous anomaly and microbleeding in STN. Neurology 2014 0.76
38 Identification and treatment of cervical and oromandibular dystonia in acutely brain-injured patients. Neurocrit Care 2005 0.76
39 Consideration of gene therapy for paediatric neurotransmitter diseases. J Inherit Metab Dis 2009 0.75
40 Neuroprotective therapy in Parkinson's disease: current status and new directions from experimental and genetic clues. J Clin Neurol 2005 0.75
41 Parkinson's disease biomarkers: resources for discovery and validation. Neuropsychopharmacology 2014 0.75
42 Diagnostic biomarkers of Parkinson's disease: what gain at what cost? J Neurol Neurosurg Psychiatry 2012 0.75
43 Biomarkers in neuropsychiatric diseases. Neurobiol Dis 2009 0.75